Moteur de recherche d’entreprises européennes
Financement de l’UE (5 507 441 €) : In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy Hor01/06/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy
According to the 2014 European Society of Cardiology Guidelines, cardiomyopathies are defined as structural and functional abnormalities of the ventricular myocardium that are unexplained by flow limiting coronary artery disease or abnormal loading conditions. There are four major classifications of cardiomyopathy: hypertrophic (HCM), dilated (DCM), restrictive (RCM), and arrhythmogenic right ventricular (ARVC). Familial cardiomyopathies (FCM) are most commonly diagnosed, or progress of the disease is monitored, through in vivo imaging, with either echocardiography or, increasingly, cardiac magnetic resonance imaging (MRI). The treatment of symptoms of FCM by established therapies could only in part improve the outcome, but novel therapies need to be developed to affect the disease process and time course more fundamentally. SILICOFCM project will develop in silico computational cloud platform which will integrate from stopped-flow molecular kinetic assays to magnetic resonance imaging of the whole heart, bioinformatics and image processing tools with state of the art computer models with the aim to reduce animal and clinical studies for a new drug development and optimized clinical therapy of FCM. The developed system will be distributed on the cloud platforms in order to achieve efficient data storage and high-performance computing, that can offer end users results in reasonably short time. Academic technical partners IIT, UOI, UL and BSC will be responsible for developing and integration of in silico cloud computational platform with multi-scale cardiac muscle modelling which include experiments on protein mutation in vitro from UNIKENT, UNIFI and UW. Bioinformatics tools will be integrated by US company SBG. Clinical partners UNEW, ICVDV, UPMC and UHREG will do retrospective and prospective studies. SME partner R-Tech will be in charge of regulatory issues and reports and BIOIRC will do the exploitation of the project.
| Barcelona Supercomputing Center Centro Nacional de Supercomputacion | 342 375 € |
| Faculty OF Medicine, University OF Belgrade | 180 250 € |
| ILLINOIS INSTITUTE OF TECHNOLOGY | 417 750 € |
| Institut ZA Kardiovaskularne Bolesti Vojvodine | 445 750 € |
| Istrazivacko Razvojni Centar ZA Bioinzenjering Bioirc d.o.o. | 721 750 € |
| KLINIKUM DER UNIVERSITAET REGENSBURG | 374 625 € |
| Panepistimio Ioanninon | 276 375 € |
| Seven Bridges Genomics Biyoteknoloji Anonim Sirketi | 0,00 € |
| Seven Bridges Genomics d.o.o. Beograd | 0,00 € |
| SEVEN BRIDGES GENOMICS Inc. | 339 375 € |
| Seven Bridges Genomics UK Ltd. | 0,00 € |
| Sorbonne Universite | 0,00 € |
| STEINBEIS EU-VRI GmbH | 278 750 € |
| Universita Degli Studi Di Firenze | 475 100 € |
| University of Kent | 413 550 € |
| University of Newcastle Upon Tyne | 604 090 € |
| University OF Novi SAD, Faculty OF Medicine Novi SAD | 0,00 € |
| UNIVERSITY OF WASHINGTON | 450 201 € |
| Univerza V Ljubljani | 187 500 € |
https://cordis.europa.eu/project/id/777204
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
